Revance Therapeutics Inc (RVNC) was Reiterated by Piper Jaffray to “Overweight” while Lowering the Price Target of the company shares to $ 35 from a previous price target of $54 . Piper Jaffray advised their investors in a research report released on Jun 14, 2016.
Many Wall Street Analysts have commented on Revance Therapeutics Inc. Revance Therapeutics Inc was Downgraded by Brean Capital to ” Hold” on Jun 14, 2016. Sun Trust Rbsn Humphrey Initiated Revance Therapeutics Inc on Mar 23, 2016 to “Buy”, Price Target of the shares are set at $46.
On the company’s financial health, Revance Therapeutics Inc reported $-0.71 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on May 9, 2016. Analyst had a consensus of $-0.83.Analysts expectations of $ .08.During the same quarter in the previous year, the company posted $-0.65 EPS.
Revance Therapeutics Inc closed down -0.73 points or -3.80% at $18.46 with 1,47,653 shares getting traded on Friday. Post opening the session at $19, the shares hit an intraday low of $18.28 and an intraday high of $19.29 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on May 11, 2016, Curtis Ruegg (EVP, Technical Operations) sold 1,000 shares at $16.18 per share price. According to the SEC, on Nov 18, 2015, Arthur Peter Bertolino (EVP and Chief Medical Officer) sold 7,753 shares at $39.33 per share price.
Revance Therapeutics Inc. is a clinical-stage specialty biopharmaceutical company. The Company is focused on the development manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through two dose formulations topical product candidate RT001 and injectable product candidate RT002. RT001 is a non-injectable dose form. RT001 is being studied for aesthetic indications such as crow’s feet lines (wrinkles around the eyes) and therapeutic indications such as hyperhidrosis (excessive sweating). It is in a Phase III development program of RT001 in North America for the treatment of crow’s feet lines. RT002 is an injectable formulation of botulinum toxin designed to be targeted and longer lasting. RT002 is being studied for aesthetic indications such as glabellar (frown) lines and therapeutic uses such as muscle movement disorders.